Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23476958 | 1.00 | STING1 (1.00) | STING1 | |
| SCHEMBL18511079 | 1.00 | STING1 (1.00) | STING1 | |
| SCHEMBL29881510 | 1.00 | STING1 (1.00) | STING1 | |
| SCHEMBL21417488 | 1.00 | STING1 (1.00) | STING1 | |
| SCHEMBL24703846 | 1.00 | STING1 (1.00) | STING1 | |
| SCHEMBL22887325 | 0.95 | STING1 (1.00) | STING1 | |
| SCHEMBL17858719 | 0.95 | STING1 (1.00) | STING1 | |
| SCHEMBL21343493 | 0.95 | STING1 (1.00) | STING1 | |
| SCHEMBL24209547 | 0.95 | STING1 (0.92) | STING1 | |
| SCHEMBL23477154 | 0.94 | STING1 (1.00) | STING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241089-A1 | STING AGONIST COMPRISING EXOSOMES FOR TREATING NEUROIMMUNOLOGICAL DISORDERS | CODIAK BIOSCIENCES, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| US-11667664-B2 | Cyclic dinucleotides for cytokine induction | KAYLA THERAPEUTICS (FR) | 2023-06-06 | — | — | US | disclosed |
| US-11667664-B2 | Cyclic dinucleotides for cytokine induction | KAYLA THERAPEUTICS (FR) | 2023-06-06 | — | — | US | disclosed |
| US-20220168415-A1 | EXTRACELLULAR VESICLES FOR VACCINE DELIVERY | CODIAK BIOSCIENCES, INC. (US) | 2022-06-02 | — | — | US | disclosed |
| US-20220017561-A1 | CYCLIC DINUCLEOTIDES FOR CYTOKINE INDUCTION | KAYLA THERAPEUTICS (FR) | 2022-01-20 | — | — | US | disclosed |
| US-20210322327-A1 | EXTRACELLULAR VESICLES COMPRISING STING-AGONIST | LONZA SALES AG (CH) | 2021-10-21 | — | — | US | disclosed |
| US-11053272-B2 | Cyclic dinucleotides for cytokine induction | KAYLA THERAPEUTICS (FR) | 2021-07-06 | — | — | US | disclosed |
| US-20200255469-A1 | CYCLIC DINUCLEOTIDES FOR CYTOKINE INDUCTION | KAYLA THERAPEUTICS (FR) | 2020-08-13 | — | — | US | disclosed |
| US-10562929-B2 | Cyclic dinucleotides for cytokine induction | KAYLA THERAPEUTICS (FR) | 2020-02-18 | — | — | US | disclosed |
| EP-3233882-B1 | FLUORINATED CYCLIC DINUCLEOTIDES FOR CYTOKINE INDUCTION | KAYLA THERAPEUTICS (FR) | 2019-10-30 | — | — | EP | disclosed |
| EP-3546473-A1 | CYCLIC [(2',5')P(3',5')P]-DINUCLEOTIDES FOR CYTOKINE INDUCTION | Kayla Therapeutics (FR) | 2019-10-02 | — | — | EP | disclosed |
| US-10011630-B2 | Cyclic dinucleotides for cytokine induction | INVIVOGEN (FR) | 2018-07-03 | — | — | US | disclosed |
| US-10011630-B2 | Cyclic dinucleotides for cytokine induction | INVIVOGEN (FR) | 2018-07-03 | — | — | US | disclosed |
| US-20170340658-A1 | COMBINED USE OF A CHEMOTHERAPEUTIC AGENT AND A CYCLIC DINUCLEOTIDE FOR CANCER TREATMENT | INVIVOGEN (FR) | 2017-11-30 | — | — | US | disclosed |
| US-20170340658-A1 | COMBINED USE OF A CHEMOTHERAPEUTIC AGENT AND A CYCLIC DINUCLEOTIDE FOR CANCER TREATMENT | INVIVOGEN (FR) | 2017-11-30 | — | — | US | disclosed |
| US-20160362441-A1 | CYCLIC DINUCLEOTIDES FOR CYTOKINE INDUCTION | KAYLA THERAPEUTICS (FR) | 2016-12-15 | — | — | US | disclosed |
| US-20160362441-A1 | CYCLIC DINUCLEOTIDES FOR CYTOKINE INDUCTION | KAYLA THERAPEUTICS (FR) | 2016-12-15 | — | — | US | disclosed |
| WO-2016096174-A1 | FLUORINATED CYCLIC DINUCLEOTIDES FOR CYTOKINE INDUCTION | INVIVOGEN (FR) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016096577-A1 | COMBINED USE OF A CHEMOTHERAPEUTIC AGENT AND A CYCLIC DINUCLEOTIDE FOR CANCER TREATMENT | INVIVOGEN (FR) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362441-A1 | CYCLIC DINUCLEOTIDES FOR CYTOKINE INDUCTION | IL1B, IFNG, IFNAR1 | STING1 4/4885 |
| US-20170340658-A1 | COMBINED USE OF A CHEMOTHERAPEUTIC AGENT AND A CYCLIC DINUCLEOTIDE FOR CANCER TREATMENT | STING1, CGAS, TLR9 | STING1 1/4885 |
| US-20230241089-A1 | STING AGONIST COMPRISING EXOSOMES FOR TREATING NEUROIMMUNOLOGICAL DISORDERS | STING1, TLR9, TBK1 | STING1 1/4885 |
| US-11053272-B2 | Cyclic dinucleotides for cytokine induction | IL1B, IFNG, IFNAR1 | STING1 4/4885 |
| US-20200255469-A1 | CYCLIC DINUCLEOTIDES FOR CYTOKINE INDUCTION | IL1B, IFNG, IFNAR1 | STING1 4/4885 |
| US-10011630-B2 | Cyclic dinucleotides for cytokine induction | IL1B, IFNG, IFNAR1 | STING1 4/4885 |
| US-20220017561-A1 | CYCLIC DINUCLEOTIDES FOR CYTOKINE INDUCTION | IL1B, IFNG, IFNAR1 | STING1 4/4885 |
| US-20210322327-A1 | EXTRACELLULAR VESICLES COMPRISING STING-AGONIST | STING1, MAVS, IRF3 | STING1 1/4885 |
| US-11667664-B2 | Cyclic dinucleotides for cytokine induction | IL1B, IFNG, IFNAR1 | STING1 4/4885 |
| US-10562929-B2 | Cyclic dinucleotides for cytokine induction | IL1B, IFNG, IFNAR1 | STING1 4/4885 |
| US-20220168415-A1 | EXTRACELLULAR VESICLES FOR VACCINE DELIVERY | HAVCR2, CD74, HMGB1 | STING1 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.